Graves’ Disease During Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Thyrotoxicosis is an adverse event associated with immune checkpoint inhibitors (ICPis) that occurs in 0.6 to 3.2% of treated patients, depending on ICPi class. Presentation usually consists of a biphasic thyroiditis with transient thyrotoxicosis and secondary hypothyroidism. ICPi-induced Graves’ di...
Main Authors: | Mathilde Peiffert, Christine Cugnet-Anceau, Stephane Dalle, Karim Chikh, Souad Assaad, Emmanuel Disse, Gérald Raverot, Françoise Borson-Chazot, Juliette Abeillon-du Payrat |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1944 |
Similar Items
-
Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up
by: Manon Levy, et al.
Published: (2020-10-01) -
Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
by: Lian Duan, et al.
Published: (2020-04-01) -
Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01) -
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
by: Naoko Okura, et al.
Published: (2020-06-01) -
Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
by: Meng H. Tan, et al.
Published: (2019-01-01)